0001104659-23-030113.txt : 20230308 0001104659-23-030113.hdr.sgml : 20230308 20230308161611 ACCESSION NUMBER: 0001104659-23-030113 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230308 DATE AS OF CHANGE: 20230308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 23716321 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 10-K/A 1 tm238714d1_10ka.htm FORM 10-K/A
0001070081 true --12-31 2022 FY false 0001070081 2022-01-01 2022-12-31 0001070081 2022-06-30 0001070081 2023-02-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-K/A

(Amendment No. 1)

 

 

(Mark One)    
x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  

 

For the fiscal year ended: December 31, 2022

 

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  

 

Commission file number: 001-35969

 

 

PTC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware 04-3416587
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
   
100 Corporate Court  
South Plainfield, NJ 07080
(Address of principal executive offices) (Zip Code)

 

(908) 222-7000

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol (s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   PTCT   Nasdaq Global Select Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x    No ¨

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨    No x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x    No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer x Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company ¨
    Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨    No x

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ¨

 

The aggregate market value of the Common Stock held by non-affiliates of the registrant, based upon the last sale price of the Common Stock reported on the Nasdaq Global Select Market on June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, was $2,129,532,394. For purposes of this calculation, shares of Common Stock held by directors and officers have been treated as shares held by affiliates.

 

As of February 16, 2023, the registrant had 73,815,144 shares of Common Stock, $0.001 par value per share, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant’s 2023 Annual Meeting of Shareholders which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2022.

 

 

Auditor Name
Auditor Firm ID
Auditor

   

 

 

EXPLANATORY NOTE

 

This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) to the Annual Report on Form 10-K of PTC Therapeutics, Inc. (the “Company”) for the year ended December 31, 2022, originally filed with the Securities and Exchange Commission (the “SEC”) on February 21, 2023 (the “Original Filing”), is being filed solely for the purpose of amending Item 15, Exhibits and Financial Statement Schedules, of Part IV, to add reference to new Exhibits 10.57, 10.58 and 10.59. References in the exhibit index to these exhibits, which are incorporated by reference to prior filings by the Company with the SEC, were inadvertently omitted from the Original Filing due to an administrative error.

 

In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by our principal executive officer and principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act are filed as exhibits to this Amendment No. 1.

 

This Amendment No. 1 does not update or amend the Company’s financial statements or any other items in the Original Filing in any way other than as described in the preceding paragraphs, and the Original Filing, as amended by this Amendment No. 1, continues to speak as of the date of the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing and the Company’s other filings with the SEC.

 

   

 

 

PART IV

 

Item 15.   Exhibits and Financial Statement Schedules

 

Financial Statements

 

The response to this portion of Item 15 is incorporated by reference from the Original Filing into this Amendment.

 

Exhibits

 

Those exhibits required to be filed with the Annual Report on Form 10-K by Item 601 of Regulation S-K are listed in the exhibit index below.

 

Exhibit Index

 

Exhibit
Number		   Description of Exhibit
2.1††   Asset Purchase Agreement, dated March 15, 2017, between PTC Therapeutics, Inc. and Complete Pharma Holdings, LLC (f/k/a Marathon Pharmaceuticals, LLC) (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on March 16, 2017)
     
2.2   Amendment to Asset Purchase Agreement, dated April 20, 2017, between PTC Therapeutics, Inc. and Complete Pharma Holdings, LLC (f/k/a Marathon Pharmaceuticals, LLC) (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on April 20, 2017)
     
2.3†   Agreement and Plan of Merger, dated July 19, 2018, by and among PTC Therapeutics, Inc., Agility Merger Sub, Inc., Agilis Biotherapeutics, Inc. and, solely in its capacity as equityholder representative, Shareholder Representative Services LLC (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on July 19, 2018)
     
2.4*   Asset Purchase Agreement by and between PTC Therapeutics, Inc. and BioElectron Technology Corporation, dated October 1, 2019 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on October 30, 2019)
     
2.5*   Agreement and Plan of Merger, dated May 5, 2020, by and among PTC Therapeutics, Inc., Hydro Merger Sub, Inc., Censa Pharmaceuticals Inc. and, solely in its capacity as securityholder representative, Shareholder Representative Services LLC (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on May 6, 2020)
     
3.1   Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed by the Registrant on July 29, 2021)
     
3.2   Amended and Restated Bylaws of the Registrant, effective December 5, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on December 6, 2022)
     
4.1   Description of Registered Securities (incorporated by reference to Exhibit 4.1 to the Annual Report on Form 10-K filed by the Registrant on February 22, 2022)
     
4.2   Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)

 

   

 

 

Exhibit
Number		   Description of Exhibit
4.3   Indenture (including Form of Notes), dated as of September 20, 2019, by and between PTC Therapeutics, Inc. and U.S. Bank National Association, a national banking association, as trustee (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Registrant on September 20, 2019)
     
10.1+   2009 Equity and Long Term Incentive Plan, as amended (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.2+   Form of Notice of Award for Incentive Stock Option under 2009 Equity and Long Term Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.3+   Form of Notice of Award for Nonstatutory Stock Option under 2009 Equity and Long Term Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.4+   Form of Restricted Stock Agreement under 2009 Equity and Long Term Incentive Plan (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.5+   2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.6+   Form of Restricted Stock Agreement under 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.7+   Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.8+   PTC Therapeutics, Inc. Amended and Restated 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on June 9, 2022)
     
10.9+   Form of Incentive Stock Option Agreement under 2013 Long Term Incentive Plan—2013/2014 (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.10+   Form of Nonstatutory Stock Option Agreement under 2013 Long Term Incentive Plan—2013/2014 (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.11+   Form of Nonqualified Stock Option Agreement Inducement Grant Agreement—2014-2022 (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K filed by the Registrant on March 2, 2015)
     
10.12+   Form of Incentive Stock Option Agreement under 2013 Long Term Incentive Plan—2014-2022 (incorporated by reference to Exhibit 10.15 to the Annual Report on Form 10-K filed by the Registrant on March 2, 2015)
     
10.13+   Form of Nonstatutory Stock Option Agreement under 2013 Long Term Incentive Plan—2014-2022 (incorporated by reference to Exhibit 10.16 to the Annual Report on Form 10-K filed by the Registrant on March 2, 2015)

 

   

 

 

Exhibit
Number		   Description of Exhibit
10.14+   Form of Nonstatutory Stock Option Agreement under 2013 Long Term Incentive Plan—Non-employee Director (incorporated by reference to Exhibit 10.31 to the Annual Report on Form 10-K filed by the Registrant on February 29, 2016)
     
10.15+   Form of Restricted Stock Unit Agreement under 2013 Long Term Incentive Plan —2016-2022 (incorporated by reference to Exhibit 10.32 to the Annual Report on Form 10-K filed by the Registrant on February 29, 2016)
     
10.16+   Form of Restricted Stock Agreement under 2013 Long Term Incentive Plan —2017-2022 (incorporated by reference to Exhibit 10.19 to the Annual Report on Form 10-K filed by the Registrant on March 16, 2017)
     
10.17+   Form of Nonqualified Restricted Stock Award Agreement Inducement Grant Agreement-2018 (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-8 (File No. 333-229126), of the Registrant)
     
10.18+   Form of Incentive Stock Option Agreement under Amended and Restated 2013 Long Term Incentive Plan (incorporated by reference to Exhibit 10.18 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
10.19+   Form of Nonstatutory Stock Option Agreement under Amended and Restated 2013 Long Term Incentive Plan (incorporated by reference to Exhibit 10.19 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
10.20+   Form of Nonstatutory Stock Option Agreement under Amended and Restated 2013 Long Term Incentive Plan—Non-employee Director (incorporated by reference to Exhibit 10.20 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
10.21+   Form of Restricted Stock Unit Agreement under Amended and Restated 2013 Long Term Incentive Plan (incorporated by reference to Exhibit 10.21 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
10.22†   Funding Agreement, dated as of May 26, 2010, by and between the Registrant and The Wellcome Trust Limited (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.23*   Amendments to the Funding Agreement, dated as of May 26, 2010, by and between the Registrant and The Wellcome Trust Limited (incorporated by reference to Exhibit 10.23 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
10.24+   Amended and Restated Employment Agreement between the Registrant and Stuart W. Peltz (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.25+   Amended and Restated Employment Agreement between the Registrant and Mark E. Boulding (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)
     
10.26+   Amended and Restated Employment Agreement between the Registrant and Neil Almstead (incorporated by reference to Exhibit 10.24 to the Registration Statement on Form S-1, as amended (File No. 333-188657), of the Registrant)

 

   

 

 

Exhibit
Number		   Description of Exhibit
10.27†   Exclusive License and Supply Agreement, dated as of May 12, 2015, as amended, by and between Faes Farma, S.A. and Complete Pharma Holdings, LLC (f/k/a Marathon Pharmaceuticals, LLC), as assigned by Complete Pharma Holdings, LLC to the Registrant on April 20, 2017 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant on August 9, 2017)
     
10.28†   Commercial Manufacturing Agreement, dated as of September 18, 2015, as amended, by and between Alcami Corporation (f/k/a/ AAI Pharma Services Corp.) and Complete Pharma Holdings, LLC (f/k/a Marathon Pharmaceuticals, LLC), as assigned by Complete Pharma Holdings, LLC to the Registrant on April 20, 2017 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant on May 3, 2022)
     
10.29+   Employment Agreement, as amended, between the Registrant and Christine Utter (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant on August 6, 2019)
     
10.30†   License and Technology Transfer Agreement, dated December 23, 2015, by and among National Taiwan University, Professor Wuh-Lian(Paul) Hwu and Agilis Biotherapeutics, Inc. (formerly Agilis Biotherapeutics, LLC) (incorporated by reference to Exhibit 10.3 on Form 10-Q filed by Registrant on November 5, 2018)
     
10.31*   License and Technology Transfer Agreement Amendment No. 2, dated December 1, 2019, by and among National Taiwan University, Professor Wu-Lian (Paul) Hwu and PTC Therapeutics GT, Inc. (incorporated by reference to Exhibit 10.42 on Form 10-K filed by Registrant on March 2, 2020)
     
10.32†   Collaboration and License Agreement, dated August 1, 2018, by and between PTC Therapeutics International Limited and Akcea Therapeutics, Inc. (incorporated by reference to Exhibit 10.3 on Form 10-Q filed by Registrant on November 5, 2018)
     
10.33   Amended and Restated 2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on June 9, 2021)
     
10.34+   Employment Agreement, as amended, between the Registrant and Emily Hill (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant on August 6, 2019)
     
10.35*   Lease Agreement dated as of August 3, 2019, by and between Bristol-Myers Squibb Company and PTC Therapeutics, Inc. (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q filed by the Registrant on October 30, 2019)
     
10.36   Irrevocable Standby Letter of Credit, dated September 3, 2019, issued by HSBC Bank USA, N.A. in favor of Bristol-Myers Squibb Company for the Account of PTC Therapeutics, Inc., as amended (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q filed by the Registrant on October 30, 2019)
     
10.37+   2020 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-8 (File No. 333-235823), of the Registrant)
     
10.38+   Form of Inducement Option Agreement under the 2020 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.4 to the Registration Statement on Form S-8 (File No. 333-235823), of the Registrant)
     
10.39+   Form of Inducement Restricted Stock Agreement under the 2020 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.5 to the Registration Statement on Form S-8 (File No. 333-235823), of the Registrant)

 

   

 

 

Exhibit
Number		   Description of Exhibit
10.40+   Amendment No. 1 to 2020 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-8 (File No. 333-251878) of the Registrant)
     
10.41+   Amendment No. 2 to 2020 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (File No. 333-251878) of the Registrant)
     
10.42+   Amendment No. 3 to 2020 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.4 to the Registration Statement on Form S-8 (File No. 333-268851), of the Registrant)
     
10.43*   First Amendment to Lease Agreement dated as of October 7, 2019 by and between Bristol-Myers Squibb Company and PTC Therapeutics, Inc. (incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K filed by the Registrant on March 2, 2020)
     
10.44*   Second Amendment to Lease Agreement dated as of March 25, 2020 by and between Bristol-Myers Squibb Company and PTC Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant on April 30, 2020)
     
10.45*   License Agreement dated as of February 8, 2016, as amended, by and between Shiratori Pharmaceutical Co. Ltd. and Censa Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant on August 5, 2020)
     
10.46*   Royalty Purchase Agreement, dated as of July 17, 2020, by and among PTC Therapeutics, Inc., RPI 2019 Intermediate Finance Trust, and, solely for the limited purposes set forth therein, Royalty Pharma PLC (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant on August 5, 2020)
     
10.47+   Employment Agreement, as amended, between the Registrant and Matthew Klein (incorporated by reference to Exhibit 10.44 to the Annual Report on Form 10-K filed by the Registrant on February 22, 2022)
     
10.48+   Employment Agreement, as amended, between the Registrant and Eric Pauwels (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q filed by the Registrant on August 5, 2020)
     
10.49*   Rights Exchange Agreement, by and among PTC Therapeutics, Inc., the Rightholders set forth therein, and, for the limited purposes set forth therein, Shareholder Representatives Services LLC, dated as of April 29, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on April 30, 2020)
     
10.50   At the Market Offering Sales Agreement, dated August 7, 2019, among PTC Therapeutics, Inc., Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed by the Registrant on August 7, 2019)
     
10.51*   Lease Agreement dated May 24, 2022, between Warren CC Acquisitions, LLC and PTC Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by Registrant on August 4, 2022)
     
10.52   Irrevocable Transferable Standby Letter of Credit, dated June 22, 2022, issued by HSBC Bank USA, N.A. in favor of Warren CC Acquisitions LLC c/o Vision Real Estate Partners for the Account of PTC Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by Registrant on August 4, 2022)

 

   

 

 

Exhibit
Number		   Description of Exhibit
10.53*   Letter Agreement re: Collaboration and License Agreement, dated July 25, 2022, by and between Akcea Therapeutics, Inc. and PTC Therapeutics International Limited (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by Registrant on October 27, 2022)
     
10.54*   Letter Agreement re: Collaboration and License Agreement, dated September 14, 2022, by and between Akcea Therapeutics, Inc. and PTC Therapeutics International Limited (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by Registrant on October 27, 2022)
     
10.55*   Credit Agreement dated as of October 27, 2022, among PTC Therapeutics, Inc., as the Borrower, each subsidiary of the Borrower from time to time party thereto, as Guarantors, the Lenders from time to time party thereto and Wilmington Trust, National Association, as Administrative Agent (incorporated by reference to Exhibit 10.55 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
10.56   Stock Purchase Agreement, dated as of October 27, 2022 by and among the investors listed therein and PTC Therapeutics, Inc. (incorporated by reference to Exhibit 10.56 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
10.57   Lease Agreement, dated as of July 11, 2000, as amended, between the Registrant and 46.24 Associates L.P. (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1, as amended (File No. 333 188657), of the Registrant)
     
10.58†   License and Collaboration Agreement, dated as of November 23, 2011, as amended, by and among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche, Inc. and Spinal Muscular Atrophy Foundation (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1, as amended (File No. 333 188657), of the Registrant)
     
10.59†   Sponsored Research Agreement, as amended dated as of June 1, 2006, by and between the Registrant and Spinal Muscular Atrophy Foundation (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1, as amended (File No. 333 188657), of the Registrant)
     
21.1   Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
23.1   Consent of Independent Registered Public Accounting Firm (incorporated by reference to Exhibit 23.1 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
24.1   Power of attorney (included on the signature page to this Form 10-K)
     
31.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.1 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
31.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.2 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
31.3   Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

 

   

 

 

Exhibit
Number		   Description of Exhibit
31.4   Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**
     
32.1   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.1 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
32.2   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporate by reference to Exhibit 32.2 to the Annual Report on Form 10-K filed by the Registrant on February 21, 2023)
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Database
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
104   Cover Page Interactive Data File (formatted Inline XBRL and contained in Exhibit 101)

 

 

††Confidential treatment has been granted as to certain portions, which portions have been omitted and separately filed with the Securities and Exchange Commission.

 

†Confidential treatment has been granted for certain portions that are omitted from this exhibit. The omitted information has been filed separately with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to the registrant’s application for confidential treatment. In addition, schedules have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the SEC upon request; provided, however, that the registrant may request confidential treatment for any document so furnished.

 

+Management contract, compensatory plan or arrangement.

 

*Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

 

**Submitted electronically herewith.

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  PTC Therapeutics, Inc.
     
Date: March 8, 2023 By: /s/ STUART W. PELTZ
    Stuart W. Peltz, Ph.D.
   

Chief Executive Officer

(Principal Executive Officer)

 

   

 

 EX-31.3 2 tm238714d1_ex31-3.htm EXHIBIT 31.3

Exhibit 31.3

 

CERTIFICATIONS

 

I, Stuart W. Peltz, certify that:

 

1.I have reviewed this Annual Report on Form 10-K of PTC Therapeutics, Inc.; and

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: March 8, 2023 By: /s/ STUART W. PELTZ
    Stuart W. Peltz
    Chief Executive Officer
    (Principal Executive Officer)

 

   

 

 EX-31.4 3 tm238714d1_ex31-4.htm EXHIBIT 31.4

Exhibit 31.4

 

CERTIFICATIONS

 

I, Emily Hill, certify that:

 

1.I have reviewed this Annual Report on Form 10-K of PTC Therapeutics, Inc.; and

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: March 8, 2023 By: /s/ EMILY HILL
    Emily Hill
    Chief Financial Officer
    (Principal Financial Officer)

 

   

 

 EX-101.SCH 4 ptct-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ptct-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Name Auditor Firm ID Auditor Location EX-101.PRE 6 ptct-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Feb. 16, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) to the Annual Report on Form 10-K of PTC Therapeutics, Inc. (the “Company”) for the year ended December 31, 2022, originally filed with the Securities and Exchange Commission (the “SEC”) on February 21, 2023 (the “Original Filing”), is being filed solely for the purpose of amending Item 15, Exhibits and Financial Statement Schedules, of Part IV, to add reference to new Exhibits 10.57, 10.58 and 10.59. References in the exhibit index to these exhibits, which are incorporated by reference to prior filings by the Company with the SEC, were inadvertently omitted from the Original Filing due to an administrative error.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 001-35969    
Entity Registrant Name PTC THERAPEUTICS, INC.    
Entity Central Index Key 0001070081    
Entity Tax Identification Number 04-3416587    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 100 Corporate Court    
Entity Address, City or Town South Plainfield    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07080    
City Area Code 908    
Local Phone Number 222-7000    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol PTCT    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 2,129,532,394
Entity Common Stock, Shares Outstanding   73,815,144  
Documents Incorporated by Reference [Text Block]

DOCUMENTS INCORPORATED BY REFERENCE

 

Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant’s 2023 Annual Meeting of Shareholders which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2022.

    
ICFR Auditor Attestation Flag true    
Auditor Name Ernst & Young LLP    
Auditor Firm ID 42    
Auditor Location Location Iselin, New Jersey    
XML 8 tm238714d1_10ka_htm.xml IDEA: XBRL DOCUMENT 0001070081 2022-01-01 2022-12-31 0001070081 2022-06-30 0001070081 2023-02-16 iso4217:USD shares iso4217:USD shares 0001070081 true --12-31 2022 FY false 10-K/A true 2022-12-31 false 001-35969 PTC THERAPEUTICS, INC. DE 04-3416587 100 Corporate Court South Plainfield NJ 07080 908 222-7000 Common Stock, $0.001 par value per share PTCT NASDAQ Yes No Yes Yes Large Accelerated Filer false false true 2129532394 73815144 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant’s 2023 Annual Meeting of Shareholders which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2022.</span></p> Ernst & Young LLP 42 Location Iselin, New Jersey This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) to the Annual Report on Form 10-K of PTC Therapeutics, Inc. (the “Company”) for the year ended December 31, 2022, originally filed with the Securities and Exchange Commission (the “SEC”) on February 21, 2023 (the “Original Filing”), is being filed solely for the purpose of amending Item 15, Exhibits and Financial Statement Schedules, of Part IV, to add reference to new Exhibits 10.57, 10.58 and 10.59. References in the exhibit index to these exhibits, which are incorporated by reference to prior filings by the Company with the SEC, were inadvertently omitted from the Original Filing due to an administrative error. EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 38 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ptcbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityShellCompany - tm238714d1_10ka.htm 25, 28 tm238714d1_10ka.htm ptct-20221231.xsd ptct-20221231_lab.xml ptct-20221231_pre.xml tm238714d1_ex31-3.htm tm238714d1_ex31-4.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm238714d1_10ka.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 38 }, "contextCount": 3, "dts": { "inline": { "local": [ "tm238714d1_10ka.htm" ] }, "labelLink": { "local": [ "ptct-20221231_lab.xml" ] }, "presentationLink": { "local": [ "ptct-20221231_pre.xml" ] }, "schema": { "local": [ "ptct-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 38, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PTCT", "nsuri": "http://ptcbio.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm238714d1_10ka.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://ptcbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm238714d1_10ka.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ptcbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-030113-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-030113-xbrl.zip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